Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Talks Up AI, Big Data, Cancer Care But Approval, Coverage Huddles Persist

Executive Summary

Leveraging the internet and big data to improve healthcare, regulatory efficiency and cancer treatment are among the priorities singled out by the Chinese Premier at the annual National People's Congress meeting. Some delegates say drug approval and coverage challenges remain, while industry observers point to commercial insurance as a solution to drive the specialty market such as cancer care.

You may also be interested in...



Zero Tariff On Anticancer Drugs To China, Will MNCs Sing Hymn?

Commonly-prescribed medicines, especially imported anticancer drugs, will potentially see zero tariffs in China, although this may be a symbolic sign rather than a substantive move to improve market access for highly-priced products, some say.

2017 A Takeoff Year For China Drug Approvals?

2017 may become a banner year for the China FDA as the agency officially joined the ICH process and began aligning more closely with the US FDA, approving over 25 innovative new drugs so far with an increasing focus on treatments for cancer, hepatitis and orphan diseases.

Pharma-BAT Digital Health Tango In China: Will It Pay Off?

China's internet giants Baidu, Alibaba and Tencent, collectively called BAT, are increasingly tapping into digital health to benefit from recent policy changes, and 2017 saw pharma companies eagerly jump onboard to share the potential gains.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel